Researchers at the Yale School of Medicine have developed a two-part vaccination strategy that successfully prevented genital herpes infection in preclinical models. Published June 19 in Science Immunology, the study uses “prime and pull” technology—an initial intramuscular injection combined with localized nanoparticle delivery—to trigger a robust immune response at the vaginal lining, a feat traditional vaccines have previously failed to achieve.
How does the ‘prime and pull’ vaccine work?
The “prime and pull” method addresses a primary hurdle in vaccine development: traditional intramuscular shots often fail to generate enough antibodies at the mucosal surfaces where viruses typically enter the body. According to senior author Akiko Iwasaki, Sterling Professor of Immunobiology at Yale, the technique works by using an initial injection to “prime” the immune system, while a second, localized treatment “pulls” those immune cells directly to the site of potential infection.
What are BEACON nanoparticles?
The researchers created a specialized nanoparticle called BEACON (Bioactive Enhanced Adjuvant Chemokine Oligonucleotide Nanoparticles). Lead author Sachin Bhagchandani, a postdoctoral researcher in the Iwasaki lab, developed the particle by linking immunostimulating DNA to a chemokine, which acts as a chemical signal to attract immune cells. In preclinical trials, 80% of mice treated with this method showed no signs of disease after six months, compared to only 40% of mice that received a standard intramuscular injection alone.
How does this compare to previous methods?
Earlier attempts to stimulate local immunity faced significant limitations. When researchers previously introduced chemokines alone, they failed to engage critical B cells, leading to only partial protection. Subsequent attempts using DNA molecules to stimulate the immune system succeeded in reducing viral load but triggered unwanted inflammation. The BEACON formulation solves both issues by precisely targeting immune cells, which allows for a lower, safer dose of DNA that prevents inflammatory side effects.
Pro Tip: Why precision matters
By targeting specific immune cells rather than affecting all cells in the area, the BEACON approach minimizes tissue inflammation. This precision is a significant step forward from earlier, broader immune-stimulation techniques that often caused collateral damage to healthy tissue.
What are the next steps for human trials?
The Yale team is currently collaborating with the Appel lab at Stanford University to explore translatable versions of the vaccine, such as a vaginal suppository. Researchers are also investigating a nasal delivery method, which could potentially make the treatment viable for men as well. While these developments are still in the preclinical phase, the ultimate goal remains human clinical trials to address the physical and social impacts of the lifelong infection.
Frequently Asked Questions
Can this vaccine cure existing genital herpes?
The current study focused on preventing infection. However, according to the research team, they are currently evaluating whether the “prime and pull” method can also be used to treat established infections.
Is this vaccine available now?
No. The research, published in Science Immunology, is currently limited to preclinical models. Human clinical trials are the next required step before the treatment can be considered for public use.
How long does the immunity last?
In the study, the immune response generated by the BEACON nanoparticles in mice lasted for at least six months, demonstrating the potential for long-term protection.
Are you interested in the latest breakthroughs in immunology and vaccine development? Subscribe to our weekly newsletter for updates on this study and other medical research, or join the conversation in the comments section below.
